Prinz J C
Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig-Maximilians-Universität München.
Hautarzt. 2005 Sep;56(9):812-8. doi: 10.1007/s00105-005-1003-9.
Efalizumab is a humanized monoclonal CD11a-antibody. It inhibits T-cell migration and activation which are essential steps in the immunopathogenesis of psoriasis. Clinical studies have demonstrated that efalizumab is efficient and safe in the treatment of chronic plaque psoriasis. Approximately 30% of patients achieve an improvement in PASI of > or =75% within 12 weeks, with further clinical benefit noted with continued therapy. Efalizumab thus appears as an important option in the long-term management of chronic plaque psoriasis.
依法利珠单抗是一种人源化抗CD11a单克隆抗体。它可抑制T细胞迁移和激活，而这是银屑病免疫发病机制中的关键步骤。临床研究表明，依法利珠单抗治疗慢性斑块状银屑病有效且安全。约30%的患者在12周内达到PASI改善≥75%，持续治疗有进一步的临床获益。因此，依法利珠单抗似乎是慢性斑块状银屑病长期管理中的一个重要选择。
